DelveInsight

Feb 16, 2018

Vertex pharmaceutical’s growth story in biotech with Symdeko’s approval FDA has recently approved Vertex Pharmaceutical’s latest combination treatment, Symdeko, to serve the cystic fibrosis patient population. Symdeko's annual list price has been set at USD 292,000. Symdeko has paired with a fresh corrector, tezacaf...

Feb 14, 2018

Gilead Sciences has recently launched a highly effective hepatitis C drug Sovaldi at a whopping price of USD 84,000 per treatment course at the same time when ‘How to price a cure’ discussion has entered the pharma industry. Gilead bought a launch-ready drug and launched it very quietly hoping that it's very cost-ef...

Feb 14, 2018

Roivant expanding its horizon into metabolic diseases segment with USD 650 million diabetes pact with Poxel Roivant Sciences has recently signed a USD 650 million deal to acquire near-global rights to Poxel pharma’s phase 3-ready Type 2 diabetes drug (imeglimin). It’s been a while since Poxel was waiting f...

Feb 12, 2018

Natural killer cells are the innate immune cells that are naturally involved in tumor immunosurveillance. These cells have direct cytotoxic activity and also secrete proinflammatory cytokines upon activation. Natural killer cells’ cytolytic activity is dependent on a balance between inhibitory signals and activating...

Feb 09, 2018

Primary Sjögren syndrome (pSS) is a.prototypical autoimmune.disease. The involvement.of B cells in the pathogenesis.of pSS has long been suspected.on the basis of clinical.observations that include the.presence of serum.autoantibodies, hypergammaglobulinemia, increased.levels of free light chains and.increased risk ...

Feb 06, 2018

Charles River to fuel hit discovery with AstraZeneca high-throughput collaboration After collaborating with AstraZeneca Charles River is now looking forward to strengthening its high-throughput screening capabilities (HTC) with the help of highly advance AstraZeneca technology. Now the company is able to offer the ...

Jan 25, 2018

Pharma startup Bonti has recently grabbed a funding of USD 15 million Managed by Ex-Allergan executives biotech startup Bonti has recently bagged a funding of USD 15.5 million in series C, The Company is focused on developing a new botulinum neurotoxin for both therapeutic and cosmetic uses. Funding will help in the...

Jan 24, 2018

Cell-Cell Interactions are essential for multiple biological processes to run smoothly, including a variety of processes like embryonic development, immunity, and neuronal signaling. Cell-cell interaction dynamics can be monitored in vivo by using intravital microscopy, but this approach does not provide a...

Jan 23, 2018

Pharma giant Celgene finally confirms USD 9 billion Juno Therapeutics buyout Celgene has finally confirmed the week-long rumor of buying Juno Therapeutics for a deal worth around USD 9 billion boosting its Grip in CAR-T therapy domain. A major reason for this buyout is Juno’s lead CAR-T drug candidate JCAR017 that ...

Jan 19, 2018

Familial Amyloid Polyneuropathy (also known as transthyretin amyloidosis, TTR, and FAP) is a group of endangering multisystem disorders which are transmitted as an autosomal dominant trait. It is caused by the excessive accumulation of amyloid in the organs and tissues. The first identified cause of FAP is the Val30...